Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment

被引:21
|
作者
Dadwal, Ushashi C. [1 ]
Chang, Eric S. [1 ]
Sankar, Uma [1 ]
机构
[1] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA
来源
关键词
castrate-resistant prostate cancer; androgen-deprivation therapy; CAMKK2; bone-tumor microenvironment; treatment induced bone loss; PROTEIN-KINASE KINASE; SKELETAL-RELATED EVENTS; DEPRIVATION THERAPY; MARROW MICROENVIRONMENT; RESPONSIVE GENES; HORMONAL-THERAPY; CAMKK2; METASTASIS; CELLS; MEN;
D O I
10.3389/fendo.2018.00335
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The skeletal system is of paramount importance in advanced stage prostate cancer (PCa) as it is the preferred site of metastasis. Complex mechanisms are employed sequentially by PCa cells to home to and colonize the bone. Bone-resident PCa cells then recruit osteoblasts (OBs), osteoclasts (OCs), and macrophages within the niche into entities that promote cancer cell growth and survival. Since PCa is heavily reliant on androgens for growth and survival, androgen-deprivation therapy (ADT) is the standard of care for advanced disease. Although it significantly improves survival rates, ADT detrimentally affects bone health and significantly increases the risk of fractures. Moreover, whereas the majority patients with advanced PCa respond favorably to androgen deprivation, most experience a relapse of the disease to a hormone-refractory form within 1-2 years of ADT. The tumor adapts to surviving under low testosterone conditions by selecting for mutations in the androgen receptor (AR) that constitutively activate it. Thus, AR signaling remains active in PCa cells and aids in its survival under low levels of circulating androgens and additionally allows the cancer cells to manipulate the bone microenvironment to fuel its growth. Hence, AR and its downstream effectors are attractive targets for therapeutic interventions against PCa. Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2), was recently identified as a key downstream target of AR in coordinating PCa cell growth, survival, and migration. Additionally, this multifunctional serine/threonine protein kinase is a critical mediator of bone remodeling and macrophage function, thus emerging as an attractive therapeutic target downstream of AR in controlling metastatic PCa and preventing ADT-induced bone loss. Here, we discuss the role played by AR-CaMKK2 signaling axis in PCa survival, metabolism, cell growth, and migration as well as the cell-intrinsic roles of CaMKK2 in OBs, OCs, and macrophages within the bone microenvironment.
引用
收藏
页数:11
相关论文
共 50 条
  • [11] Molecular modelling of the androgen receptor axis: rational basis for androgen receptor intervention in androgen-independent prostate cancer
    Fletterick, RJ
    BJU INTERNATIONAL, 2005, 96 : 2 - 9
  • [12] A novel approach for targeting androgen receptor signaling axis in prostate cancer
    Kaochar, Salma
    Foley, Christopher
    Coarfa, Cristian
    Mitsiades, Nicholas
    CANCER RESEARCH, 2017, 77
  • [13] Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer
    Fernandes, Rayzel C.
    Hickey, Theresa E.
    Tilley, Wayne D.
    Selth, Luke A.
    ENDOCRINE-RELATED CANCER, 2019, 26 (05) : R237 - R257
  • [14] Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis
    Ghashghaei, M.
    Kucharczyk, M.
    Elakshar, S.
    Muanza, T.
    Niazi, T.
    CURRENT ONCOLOGY, 2019, 26 (05) : E640 - E650
  • [15] Androgen receptor, PARP signaling, and tumor microenvironment: the 'perfect triad' in prostate cancer?
    Garofoli, Marianna
    Maiorano, Brigida Anna
    Bruno, Giuseppina
    Giordano, Guido
    Di Tullio, Piergiorgio
    Maselli, Felicia Maria
    Landriscina, Matteo
    Conteduca, Vincenza
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [16] Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome
    Leach, Damien A.
    Need, Eleanor F.
    Toivanen, Roxanne
    Trotta, Andrew P.
    Palenthorpe, Helen M.
    Tamblyn, David J.
    Kopsaftis, Tina
    England, Georgina M.
    Smith, Eric
    Drew, Paul A.
    Pinnock, Carole B.
    Lee, Peng
    Holst, Jeff
    Risbridger, Gail P.
    Chopra, Samarth
    DeFranco, Donald B.
    Taylor, Renea A.
    Buchanan, Grant
    ONCOTARGET, 2015, 6 (18) : 16135 - 16150
  • [17] Androgen receptor signaling affects macrophage differentiation in the human prostate cancer microenvironment
    Cioni, Bianca
    Nevedomskaya, Ekatarina
    Stelloo, Suzan
    Melis, Monique
    van Burgsteden, Johan
    de Jong, Jeroen
    van der Poel, Henk
    de Boer, Jan Paul
    Zwart, Wilbert
    Bergman, Andries M.
    CANCER RESEARCH, 2018, 78 (13)
  • [18] A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer
    McAllister, Milly J.
    Underwood, Mark A.
    Leung, Hing Y.
    Edwards, Joanne
    TRANSLATIONAL RESEARCH, 2019, 206 : 91 - 106
  • [19] The androgen axis in recurrent prostate cancer
    Mohler, JL
    Gregory, CW
    Ford, OH
    Kim, D
    Weaver, CM
    Petrusz, P
    Wilson, EM
    French, FS
    CLINICAL CANCER RESEARCH, 2004, 10 (02) : 440 - 448
  • [20] ANDROGEN AXIS DISRUPTION IN PROSTATE CANCER
    Schiewer, Matthew J.
    Goodwin, Jonathan F.
    Brenner, J. Chad
    Augello, Michael A.
    Liu, Fengzhi
    Planck, Jamie L.
    Schrecengost, Randy S.
    Feng, Felix Y.
    Chinnaiyan, Anil M.
    Dicker, Adam P.
    Brody, Jonathan R.
    Pascal, John M.
    Knudsen, Karen E.
    JOURNAL OF ANDROLOGY, 2012, 33 (02): : 30 - 30